Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05552326 · ClinicalTrials.gov registry record · Phase 3
A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia
A Phase 3 study of Severe Hypertriglyceridemia, sponsored by Ionis Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 446
- Enrollment target
- 20
- Study locations
NCT05552326 is a Phase 3 study of Severe Hypertriglyceridemia that has completed, run by Ionis Pharmaceuticals. The registered enrollment target is 446 participants, above the 369-participant average among 8 other Severe Hypertriglyceridemia trials with a reported enrollment target (21% higher). The trial reports 20 study locations across 6 states.
The verdict
NCT05552326, a Phase 3 study of Severe Hypertriglyceridemia, has completed, sponsored by Ionis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 446 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to evaluate the efficacy of olezarsen as compared to placebo on the percent change in fasting triglycerides (TG) from baseline.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Olezarsen
Study Locations (20)
Florida
- Accel Research Sites - DeLand
- Finlay Medical Research - Greenacres City
- University of Florida Jacksonville - Jacksonville
- Meridien Research - Maitland
- Columbus Clinical Services - Miami
- Harmony Clinical Research, Inc - North Miami Beach
- Combined Research Orlando Phase I-IV - Orlando
- 3Sync Research - Sunrise
- R & B Medical Center LLC - Tampa
- JSV Clinical Research Study, Inc. - Tampa
- Metabolic Research Institute - West Palm Beach
Georgia
- Emory University - Atlanta
- Accel Clinical Research - Eatonton
- Northeast Georgia Medical Center - Gainesville
- Randomize Now - Newnan
Alabama
- Central Research Associates, Inc. - Birmingham
- Alabama Clinical Therapeutics, LLC Alabaster - Birmingham
Arizona
- Onyx Clinical Research - Peoria
California
- NRC Research Institute - Los Angeles
Indiana
- St. Vincent Medical Group - Carmel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 446 participants |
| Start Date | 2022-08-31 |
| Est. Completion | 2025-09-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05552326
The ClinicalTrials.gov registry entry for NCT05552326 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 446 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 369-participant average among 8 other Severe Hypertriglyceridemia trials with a reported enrollment target (21% higher). The listed sponsor is Ionis Pharmaceuticals, which has 76 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Severe Hypertriglyceridemia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05552326 reports 20 study locations spanning 6 distinct geographic areas - top geographies include Florida, Georgia, Alabama.
Frequently Asked Questions
What is clinical trial NCT05552326 about?
NCT05552326 is a clinical study titled "A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia". The purpose of this study is to evaluate the efficacy of olezarsen as compared to placebo on the percent change in fasting triglycerides (TG) from baseline.
What is the current status of trial NCT05552326?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 446 participants. The study started on 2022-08-31. Estimated completion is 2025-09-12.
What conditions does trial NCT05552326 study?
This clinical trial studies the following conditions: Severe Hypertriglyceridemia.
What interventions are being tested in trial NCT05552326?
The interventions under investigation include: Placebo (DRUG), Olezarsen (DRUG).
Who is sponsoring clinical trial NCT05552326?
This trial is sponsored by Ionis Pharmaceuticals, which has 76 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05552326 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Severe Hypertriglyceridemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis
RECRUITING · Phase 3
-
CORE-OLE: A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants With Severe Hypertriglyceridemia (SHTG)
ACTIVE NOT RECRUITING · Phase 3
-
To Evaluate the Efficacy and Safety of Pegozafermin in Subjects With Severe Hypertriglyceridemia
ACTIVE NOT RECRUITING · Phase 3
-
Study of Plozasiran in Adults With Severe Hypertriglyceridemia
ACTIVE NOT RECRUITING · Phase 3
-
Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia
ACTIVE NOT RECRUITING · Phase 3
-
Study to Evaluate the Efficacy and Safety of K-877 in Adult Patients With Fasting High Triglyceride Levels and Normal Renal Function
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.